12 Feb 2020

VENOUS SYMPOSIUM 2020: 29 sessions and new aesthetic vein course offered March 18-21

  The Venous Symposium 2020 will convene its 11th annual conference March 19-21 at the Sheraton New York Times Square Hotel, including a Latin language program. VS 2020 has scheduled 29 educational sessions, as well as an aesthetic vein course before the conference begins. In addition, VS also welcomes physicians

0
03 Dec 2019

IAC CONDUCTS ACCREDITATION PERCEPTIONS SURVEY

Authentic Testing has been engaged by the Intersocietal Accreditation Commission (IAC) to understand perceptions related to the value of imaging and procedural accreditation across multiple medical specialties. The results of the survey will help guide future quality initiatives to meet the needs of the medical community and to improve the

0
26 Jun 2019

ROYAL PHILIPS SELLS U.S. HEALTHCARE headquarters

    Amsterdam-based Royal Philips sold its Andover, Mass.-based healthcare headquarters to Atlantic Management Corp. May 4 in a deal worth $36 million. Royal Philips has been transferring its 1,900 employees to facilities in Cambridge, Massachusetts, and Nashville, Tennessee, since January. Atlantic Management, which paid $36 million for the facility,

0
26 Jun 2019

CHARING CROSS 2019: MEDTRONIC EXPANDS ON KEY AORTIC SOLUTIONS FOR CHALLENGING ANATOMIES

  Medtronic plc released new data on endovascular repair of abdominal aortic aneurysm (AAA) patients with the Endurant II/IIs stent graft system in combination with Heli-FX EndoAnchor implants and for the Valiant Navion thoracic stent graft system for thoracic endovascular repair (TEVAR). The data, which was presented at the Charing Cross

0
26 Jun 2019

ABBVIE ACQUIRING ALLERGAN AS HEDGE AGAINST EXPIRATION OF HUMIRA PATENT

As a hedge against the 2023 expiration of its U.S. patents that protect its blockbuster drug, Humira, AbbVie Inc. will acquire Dublin, Ireland-based Allergan for $63 billion in cash and stock.     Humira sales account for more than 60 percent of AbbVie’s revenue, but biosimilar drugs approved in Europe

0
25 Jun 2019

FUZZY MATH: Sanders’ Claim That Cost Barriers To HealthCare Kill 30,000 A Year IS only half true  

    TWEET “30,000 Americans a year die waiting for health care because of the cost.” –Sen. Bernie Sanders (I-Vt.), in a tweet June 20 By Shefali Luthra “Medicare for All” — or single-payer health care — is a flagship issue for Democratic presidential candidate and Vermont Sen. Bernie Sanders. So

0
19 Jun 2019

VSA, PRACTICE MANAGEMENT FIRM, OBSERVES 17TH YEAR

  Vein Centers of America (VSA) is celebrating its 17th anniversary by offering a complimentary phone consultation with President and CEO David Schmiege.              in vein-specific practice management, marketing and revenue cycle management initiatives nationwide. “We have the experience, flexibility, structure and size to implement results quickly and to create the culture

0
12 Jun 2019

VICI VENOUS STENT: FDA OKs VICI Venous Stent to treat Iliofemoral obstructive disease

    The U.S Food and Drug Administration has approved Boston Scientific’s VICI Venous Stent System for the treatment of iliofemoral venous obstructive disease, which occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked by a blood clot or compressed by anatomical anomalies.

0
12 Jun 2019

VECLOSE EXTENSION STUDY: Five-year outcomes prove durability, safety, efficacy of VenaSeal Closure System

    By Larry Storer Five-year results from the 2019 VeClose Extension Study of the Medtronic VenaSeal Closure System demonstrate that the treatment modality is consistent, durable and safe for permanently closing veins in patients with venous reflux disease. When compared with Medtronic Radiofrequency Ablation, VenaSeal continued to show “non-inferiority”

0
12 Jun 2019

MERZ REGAINS SOLE DISTRIBUTION OF ASCLERA FROM ANGIODYNAMICS

  Merz North America Inc. has regained exclusive distribution of Asclera (polidocanol) Injection in the United States to all healthcare practitioners and phlebologists treating varicose veins. Also effective April 8, AngioDynamics Inc. is no longer an authorized distributor of Asclera. All HCPs will now be able to purchase Asclera directly

0